Payment overview · 2025
General Payments
$426.01
31 reported records · 7 companies
Healthcare provider profile · identity verified
Jonathan Cross Campbell, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MOBILE, AL · NPI 1821065509
Verified facts
What the public records show
CMS Open Payments records show Jonathan Cross Campbell, MD received $426.01 in general payments during 2025 across 31 reported records.
Novo Nordisk Inc accounted for 51.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $219.38 | 51.5% | 21 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $46.89 | 11.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.22 | 10.6% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $41.02 | 9.6% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $27.77 | 6.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $26.70 | 6.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.03 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $393.74 | 30 |
| Education | $32.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $187.11 | 20 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $94.24 | 10 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $46.89 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $45.22 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $41.02 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.19 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $27.77 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $26.70 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 140 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 139 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 66 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
140 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
65 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
139 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Tramadol Hcl | Tramadol Hcl | 506 | 76 |
| Clonazepam | Clonazepam | 495 | 57 |
| Gabapentin | Gabapentin | 342 | 62 |
| Atorvastatin Calcium | Atorvastatin Calcium | 290 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 284 | 85 |
| Lisinopril | Lisinopril | 240 | 73 |
| Tizanidine Hcl | Tizanidine Hcl | 236 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 232 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 218 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 212 | 62 |
| Omeprazole | Omeprazole | 211 | 62 |
| Metformin Hcl | Metformin Hcl | 181 | 47 |
| Losartan Potassium | Losartan Potassium | 177 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 163 | 52 |
| Pregabalin | Pregabalin | 161 | 21 |
| Levothyroxine Sodium | Levothyroxine Sodium | 155 | 49 |
| Promethazine Hcl | Promethazine Hcl | 153 | 18 |
| Mounjaro | Tirzepatide | 140 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 139 | 48 |
| Ozempic | Semaglutide | 139 | 26 |
| Azithromycin | Azithromycin | 136 | 106 |
| Pantoprazole Sodium | Pantoprazole Sodium | 133 | 50 |
| Lorazepam | Lorazepam | 129 | 22 |
| Carvedilol | Carvedilol | 128 | 39 |
| Diclofenac Sodium | Diclofenac Sodium | 128 | 28 |
| Furosemide | Furosemide | 119 | 43 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 118 | 30 |
| Trazodone Hcl | Trazodone Hcl | 117 | 45 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 115 | 12 |
| Meloxicam | Meloxicam | 113 | 33 |
| Metformin Hcl Er | Metformin Hcl | 109 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 109 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 102 | 23 |
| Potassium Chloride | Potassium Chloride | 95 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 94 | 31 |
| Ondansetron Odt | Ondansetron | 93 | 21 |
| Diazepam | Diazepam | 87 | 11 |
| Meclizine Hcl | Meclizine Hcl | 87 | 27 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 85 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 18 |
| Ibuprofen | Ibuprofen | 81 | 21 |
| Montelukast Sodium | Montelukast Sodium | 77 | 26 |
| Sertraline Hcl | Sertraline Hcl | 73 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 72 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 65 | suppressed |
| Trulicity | Dulaglutide | 65 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 16 |
| Atenolol | Atenolol | 57 | 16 |
| Allopurinol | Allopurinol | 52 | 18 |
| Fluconazole | Fluconazole | 52 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 33 |
| Glimepiride | Glimepiride | 47 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | 12 |
| Celecoxib | Celecoxib | 44 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | suppressed |
| Famotidine | Famotidine | 37 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 37 | 19 |
| Jardiance | Empagliflozin | 37 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 35 | suppressed |
| Eliquis | Apixaban | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Prednisone | Prednisone | 32 | 29 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 23 |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 14 |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Simvastatin | Simvastatin | 28 | suppressed |
| Rybelsus | Semaglutide | 27 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Nystatin | Nystatin | 25 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 19 |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 15 |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 19 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 19 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $426.01 · 31 records | Novo Nordisk Inc | FARXIGA, Kerendia, MOUNJARO, Ozempic, Rybelsus, SUBLOCADE, TRELEGY ELLIPTA, TZIELD, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error